Nav: Home

New reference values for cancer patients' quality of life

January 07, 2019

Researchers and practitioners across the globe frequently use the 'EORTC' questionnaire to measure self-reported quality of life of cancer patients. For the first time, a group of researchers from Charité - Universitätsmedizin Berlin have determined general population quality of life normative data for 15 individual countries. These data allow for a more meaningful interpretation of questionnaire scores and provide information on regional differences in quality of life. The results of this study have now been published in the European Journal of Cancer*.

Have you felt any pain over the past week? Have you felt tired? Have you been worried? Across the globe, questions such as these are used to measure the health-related quality of life of cancer patients. To determine how patients feel before, during or after cancer treatment, clinicians and researchers use questionnaires such as the 'QLQ-C30' that was developed by the European Organisation for Research and Treatment of Cancer (EORTC) over 25 years ago. It is one of the most widely used questionnaires that is frequently applied as part of clinical trials but also as part of clinical routine.

Results obtained using this questionnaire can provide information on the effectiveness of a particular treatment, or serve as evidence either in favor of or against the approval of a new drug.

However, quality of life data are of limited value in the absence of 'normative values', i.e. data obtained from the general population. Such norm data allow for a more sensible interpretation of patient-reported data. An international group of researchers, led by the Health Outcomes Research Unit from Charité - Universitätsmedizin Berlin, have now successfully determined normative QLQ-C30 data as part of a large-scale study that was funded by and carried out on behalf of the EORTC Quality of Life Group. Using online surveys, the panel research company GfK collected quality of life data from more than 15,000 persons from the general population across 11 EU countries, as well as Russia, Turkey, Canada and the United States. Data from the 11 EU countries were further used to establish the 'European QLQ-C30 Norm'.

"The newly established norm values allow for a more precise interpretation of patient-reported quality of life data", explains study lead Dr. Sandra Nolte from Charité's Health Outcomes Research Unit of the Medical Department, Division of Psychosomatic Medicine. She adds: "Norm values already existed for a number of countries. However, these were usually determined using different survey methodologies, meaning that they were not suitable for use in multinational studies. For the first time, we applied consistent data collection methods across all 15 included countries, facilitating valid intra- and especially inter-country comparisons and QLQ-C30 score interpretation. This will be of benefit to researchers across the globe and, ultimately, to cancer patients."

National differences in quality of life scores came as a surprise and constituted an interesting secondary finding. While Germans reported mid-level quality of life scores, the highest scores were reported by respondents from Austria and the Netherlands. In contrast, Poland, Russia, Turkey, the United Kingdom and the United States scored significantly lower across many health-related quality of life domains. Compared to respondents from Austria or the Netherlands, respondents from these countries rated their physical and emotional health as worse and reported more fatigue and financial difficulties. "These results demonstrate the importance of using the relevant national norms when conducting country-specific studies," emphasizes Dr. Nolte. She adds: "After all, when a cancer patient reports feeling fatigued, it makes a difference whether they are from Russia or from Spain: in Russia, the general population reports significantly higher levels of fatigue than in Spain. We now have norm scores for a total of 15 individual countries. This enables us to make country-specific as well as international comparisons of cancer patients' self-reported quality of life."

The EORTC Quality of Life Questionnaire

The EORTC Quality of Life Questionnaire Core 30 (QLQ-C30) comprises 30 items (questions) that are used to assess the quality of life of cancer patients. It includes questions on the respondent's physical, cognitive, emotional and role functioning, as well as their general health and symptoms such as pain, fatigue, nausea and shortness of breath. The QLQ-C30 can be administered as either a paper-based or an electronic questionnaire. It is also available as a computer-adaptive version (EORTC CAT Core), which adapts the test in such way that only items are shown that are relevant to the individual patient. The EORTC CAT Core is readily available for use and already incorporates the new general population norm data.
-end-
*Nolte S et al., General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the United States. Eur J Cancer 107 (2019) 153-163. doi: 10.1016/j.ejca.2018.11.024

*Liegl G et al., Establishing the European Norm for the health-related quality of life domains of the computer-adaptive test EORTC CAT Core. Eur J Cancer 107 (2019) 133-141. doi: 10.1016/j.ejca.2018.11.023

Charité - Universitätsmedizin Berlin

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#532 A Class Conversation
This week we take a look at the sociology of class. What factors create and impact class? How do we try and study it? How does class play out differently in different countries like the US and the UK? How does it impact the political system? We talk with Daniel Laurison, Assistant Professor of Sociology at Swarthmore College and coauthor of the book "The Class Ceiling: Why it Pays to be Privileged", about class and its impacts on people and our systems.